Tularik Inc. (TLRK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (544)	1/12/2004 7:49:03 PM
From: scaram(o)uche	of 598

>> T71 is an orally-active, new chemical entity that was shown in preclinical studies to decrease appetite and increase metabolic rate. Discovered at Tularik, T71 acts on an undisclosed central nervous system target. Tularik intends to begin Phase 1 studies in the first quarter of this year. << >> While T607 demonstrated activity in each of HCC, ovarian cancer and gastric cancer, Tularik intends to hold T607 as a potential back-up to T67 for HCC and not pursue T607 against ovarian cancer. << >> T487 - Tularik expects to begin a Phase 2 study of T487 in patients with rheumatoid arthritis in the first quarter of this year. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next